Adial signs exclusive AD04 collaboration framework with Molteni for Europe; potential $60M in milestones and royalties

ADIAL PHARMACEUTICALS, INC.

Collaboration framework with Molteni Farmaceutici for exclusive AD04 commercialization in Europe; definitive agreement pending.
Total potential aggregate value from royalties (high single to low double digits) and milestones estimated at nearly $60M.
Molteni granted exclusivity for due diligence; upfront and milestone payments expected upon final agreement.
AD04 is a genotype-driven Alcohol Use Disorder therapy; company also advancing US partner discussions.
Special meeting on Feb 26 lacked quorum; company must call new meeting every 90 days until warrant approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.